Tag
A target-trial emulation of 4,476 matched T2DM patients with early MASLD found GLP-1RA use was associated with a 25% lower hazard of progression to high-risk FIB‑4 versus DPP‑4i (HR 0.75); no difference was seen for hard liver outcomes.
A multicenter target‑trial emulation found SGLT2 inhibitor initiation was associated with a 22% lower risk of progression to advanced fibrosis (confirmed FIB‑4 >2.67) versus DPP‑4 inhibitors in adults with MASLD and T2DM and low‑to‑inter
Pemvidutide, a dual GLP‑1/glucagon receptor agonist, reduced liver fat markedly and produced small but statistically significant reductions in AI‑quantified fibrosis over 24 weeks in phase 2 studies, but longer trials with clinical endpoint
A large prospective cohort shows phosphatidylethanol (PEth) correlates with self-reported alcohol intake but identifies frequent under-reporting; adding PEth to diagnostic pathways could improve subclassification of steatotic liver disease
A pooled analysis of three population cohorts shows lean MASLD carries higher risks of liver-related events and all-cause and liver-related mortality despite lower cardiovascular event risk compared with non-lean MASLD.
This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver healt
A 16-week RCT demonstrates that time-restricted eating significantly reduces hepatic steatosis in MASLD, offering comparable metabolic benefits to calorie restriction without adverse events.
Hypertension independently worsens clinical outcomes and liver fibrosis progression in MASLD, highlighting the need for integrated cardiovascular and hepatic care.
An evidence-based, practical summary of the IMPG consensus on standardized histologic grading and staging for MASH (MASLD) clinical trials, with recommendations for biopsy processing, feature definitions, scoring, central reading, and AI-re
This meta-analysis reveals that MetALD confers higher risks of liver-related events, hepatocellular carcinoma, and extrahepatic cancers compared to MASLD, while mortality and cardiovascular risks are similar, emphasizing tailored clinical a
Metabolic dysfunction and MASLD elevate hepatocellular carcinoma risk in chronic hepatitis B patients. The PAGE-B score effectively stratifies this risk, especially in non-cirrhotic patients, while cirrhotic patients still require careful m
A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm
Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio
Recent trials show intermittent calorie restriction (ICR) significantly reduces liver fat content in MASLD and NAFLD, especially in obese patients, offering an effective and well-tolerated alternative to conventional diets.
The LOCATE-NAFLD trial demonstrates that nurse-delivered, community-based liver screening is highly acceptable and effective for identifying high-risk MASLD patients, but faces challenges in sustainable adoption.
A 12-week hypocaloric Mediterranean diet with early time-restricted feeding improved glycaemic control and cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) compared to unrestricted timin
A double-blind RCT found that three consecutive fecal microbiota transplantations did not significantly improve hepatic steatosis or metabolic parameters in patients with MASLD, suggesting patient selection based on microbiota diversity may
Waist circumference is a superior predictor of metabolic liver diseases, outperforming BMI and other body metrics in assessing MASLD, MASH, and liver stiffness risks.
Retatrutide, a triple hormone receptor agonist, significantly reduces body fat and liver fat in patients with type 2 diabetes and MASLD, with a favorable safety profile and preservation of lean mass.
A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.
